Highland Capital Management (Tennessee)’s Carisma Therapeutics CARM Stock Holding History

Highland Capital Management (Tennessee)’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500	Closed	-$4K	–	351
2022 Q3	$4K	Hold	500	–	–	﹤0.01%	326
2022 Q2	$8K	Hold	500	–	–	﹤0.01%	323
2022 Q1	$6K	Hold	500	–	–	﹤0.01%	329
2021 Q4	$8K	Hold	500	–	–	﹤0.01%	338
2021 Q3	$8K	Hold	500	–	–	﹤0.01%	334
2021 Q2	$46K	Hold	500	–	–	﹤0.01%	326
2021 Q1	$26K	Buy	+500	New	+$23.6K	﹤0.01%	334

Other funds holding CARM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BWA

Blodgett Wealth Advisors Concord, California $126M AUM 27.65% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Highland Capital Management (Tennessee)'s CARM Position: Q4 2022 in Review

Highland Capital Management (Tennessee) sold out of Carisma Therapeutics (CARM) in Q4 2022, closing a stake of 500 shares — an estimated $4K sold.

Highland Capital Management (Tennessee) first reported a position in CARM in Q1 2021 and held it in 7 quarters. The position peaked at $46K in Q2 2021. 70 funds tracked by Wall St. Rank hold CARM as of Q4 2022.

Highland Capital Management (Tennessee) reported no remaining Carisma Therapeutics position as of Q4 2022 after selling out during the quarter.
Highland Capital Management (Tennessee) sold 500 Carisma Therapeutics shares in Q4 2022, an estimated $4K.
Highland Capital Management (Tennessee) first reported a position in Carisma Therapeutics in Q1 2021 and held it in 7 quarters.
Highland Capital Management (Tennessee)'s Carisma Therapeutics position peaked at $46K in Q2 2021.
70 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2022.

Based on Highland Capital Management (Tennessee)'s 13F filing for Q4 2022, filed 7 Feb 2023.